Evolent Health, Inc.
NYSE:EVHMedical - Healthcare Information Services
-$0.28 today
- Market cap
- $442.05M
- Beta
- 0.83
- P/E (TTM)
- -1.0
- EPS (TTM)
- -$4.44
Volume 3.10M
Average 2.78M
EVH Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Evolent Health, Inc.NYSE: EVH
Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026
Cost of revenue growth accelerates
Q1 FY2026 cost of revenue of $434.33M rose 13.9% year over year, ahead of the -20.2% change in trailing-twelve-month cost of revenue. Sequentially, it rose 4.3% from the prior quarter. Over 3 fiscal years it compounded at +15.4% a year.
Context
- Cost of revenue amounted to 84.9% of revenue in FY2025, down 0.8 pp from a year earlier.
- Cost of revenue increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +13.9% holds above the trailing-twelve-month pace of -20.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 1.59B USD
- Year-over-year change
- -27.2%
- 4-year CAGR
- +24.7%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.59B | -27.2% |
| FY2024 | 2024-12-31 | 2.19B | +45.5% |
| FY2023 | 2023-12-31 | 1.5B | +45.2% |
| FY2022 | 2022-12-31 | 1.04B | +57.5% |
| FY2021 | 2021-12-31 | 657.55M | — |
Cost of Revenue vs competitors
How EVH compares with its peers on the latest reported figures
- EVH's LTM Mar 2026 cost of revenue of $1.62B is the 2nd highest of the 11 companies compared; the peer median is $53.97M.
- Its year-over-year change of -20.2% is the 8th highest of 9, against a peer median of +16.2%.
- Cost of revenue amounts to 85.9% of revenue for EVH, versus a peer median of 43.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $2.47B | +21.6% | -17.8% | 72.4% | |
| LTM Mar 2026 | $1.62B | -20.2% | +15.4% | 85.9% | |
| LTM Mar 2026 | $462.28M | +44.5% | +28.3% | 52.5% | |
| LTM Mar 2026 | $249M | -0.1% | +7.1% | 30.0% | |
| LTM Mar 2026 | $109.48M | +10.8% | +5.6% | 35.1% | |
| LTM Mar 2026 | $55.67M | -2.6% | +1.4% | 86.3% | |
| LTM Mar 2026 | $52.28M | +55.2% | +15.2% | 50.8% | |
| LTM Mar 2026 | $6.67M | -73.5% | — | 8.4% | |
| LTM Mar 2026 | $3.83M | +1795.5% | — | 5.3% | |
| LTM Dec 2025 | $848K | — | — | — | |
| LTM Mar 2026 | $0 | — | — | — | |
| Peer median (excluding EVH) | $53.97M | +16.2% | +6.3% | 43.0% | |
Competitors are the stored peer set for EVH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 907.96M | 1.35B | 1.96B | 2.55B | 1.88B |
| Cost of Revenue | 657.55M | 1.04B | 1.5B | 2.19B | 1.59B |
| Gross Profit | 250.41M | 316.58M | 460.47M | 367.35M | 284.03M |
| Gross Margin | 27.6% | 23.4% | 23.4% | 14.4% | 15.1% |
| Research & Development | 0 | 27M | 0 | 0 | 0 |
| Selling, General & Admin | 219.5M | 269.27M | 358.11M | 263.05M | 288.47M |
| Operating Expenses | 292.82M | 312.94M | 531.68M | 407.84M | 288.47M |
| Depreciation & Amortization | 60.04M | 90.25M | 123.42M | 123.17M | 115.85M |
| EBITDA | 55.66M | 43.75M | (24.79M) | 84.85M | (361.31M) |
| EBITDA Margin | 6.1% | 3.2% | -1.3% | 3.3% | -19.3% |
| Operating Income | (42.41M) | 3.64M | (71.21M) | (40.49M) | (4.44M) |
| Operating Margin | -4.7% | 0.3% | -3.6% | -1.6% | -0.2% |
| Interest Income | 407K | 1.37M | 5.26M | 5.54M | 4.19M |
| Interest Expense | 25.43M | 15.57M | 54.21M | 24.72M | 57.47M |
| Other Income / Expenses | 12.61M | (65.72M) | (131.19M) | (22.55M) | (530.2M) |
| Income Before Tax | (29.8M) | (62.08M) | (202.41M) | (63.04M) | (534.64M) |
| Pre-Tax Margin | -3.3% | -4.6% | -10.3% | -2.5% | -28.5% |
| Income Tax Expense | 483K | (43.38M) | (89.37M) | (1.41M) | (126K) |
| Net Income | (37.6M) | (19.16M) | (113.04M) | (61.62M) | (534.51M) |
| Net Margin | -4.1% | -1.4% | -5.8% | -2.4% | -28.5% |
| EPS (Basic) | (0.36) | (0.20) | (1.28) | (0.81) | (5.07) |
| EPS (Diluted) | (0.36) | (0.20) | (1.28) | (0.81) | (5.07) |
| Weighted Avg Shares | 86.07M | 93.7M | 111.25M | 114.68M | 114.21M |
| Weighted Avg Shares (Diluted) | 86.07M | 93.7M | 111.25M | 114.68M | 114.21M |
Evolent Health, Inc.
NYSE:EVH
Intrinsic Alpha fair value
Locked
Current Price
$3.93
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.